Clinical Trial Update: A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate [Phase 4]

View source ↗

Summary

Phase 4 trial of Rituximab (MabThera) in rheumatoid arthritis patients with an inadequate response to methotrexate has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• MabThera (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Phase 4 | Status: COMPLETED | Results posted: 2015-03-19